- the 3rd oral drug for prophylaxis of thromboses after orthopedic surgery
Apixaban is an antithrombotic drug that inhibits factor Xa, and hereby the development of thrombin as well as the formation of thromboses.
Apixaban is approved for prevention of venous thromboembolism (VTE) in adult patients, who are undergoing scheduled hip or knee alloplastic surgery.
As with other new oral antithrombotics, there is no need for surveillance of coagulation parameters, and apixaban has, as well as dabigatran(link) and rivaroxaban(link,) a comparable effect and side effect profile (risk of bleeding) to that of low-molecular heparin, in relevant doses.
There are no therapeutic advantages of apicaban compared to dabigatran and rivaroxaban. Apixaban is administered 12-24 hours after an operation, dabigatran after 1-4 hours, and riveroxaban after 6-10 hours.
IRF finds, that apixaban is equal to low-molecular heparin, rivaroxaban and dabigatran. Dabigatran is at the moment somewhat cheaper than the others.
Eliquis was marketed on June 13th, 2011.
Institute for Rational Pharmacotherapy, August 23rd, 2011.